The pharmacokinetics of clofoctol in healthy neonates and adults studied by an original HPLC technique.
The pharmacokinetics of clofoctol [(tetramethyl-1,1,3,3,butyl)-4-(dichloro-2,4-benzyl)-2-hydroxy-1-benzene ] was investigated in six healthy newborns and compared with the kinetic parameters of the drug in six healthy adults. The concentration of the drug in plasma was measured by means of an original sensitive HPLC technique. In both neonates and adults treated rectally with clofoctol, the plasmatic peak occurred at the 30th min, although the maximal peak of adults was significantly lower. Kel and T1/2 exhibited a similar pattern, whereas the AUC was about 5 times higher in newborns. The present findings suggest that clofoctol is well absorbed rectally. The higher plasmatic levels of clofoctol in neonates may result from their lower degree of hepatic metabolic activity.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000097:blood / Q000378:metabolism*; D002722:Chlorobenzenes; D002851:Chromatography, High Pressure Liquid; D003408:Cresols / Q000097:blood / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D007700:Kinetics; D008297:Male; D013997:Time Factors
D000900:Anti-Bacterial Agents; D002722:Chlorobenzenes; D003408:Cresols; C018874:clofoctol